Trial reportBMC cardiovascular disorders2020
Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial.
Trial report in BMC cardiovascular disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03081949 (Peripartum Cardiomyopathy in Nigeria), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peripartum Cardiomyopathy in Nigeria (PEACE) A Registry to Study the Demographics, Social and Clinical Characteristics, Pathophysiology and Outcomes of Peripartum Cardiomyopathy in Nigeria
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Selenium nutritional status and cardiovascular diseases: mechanisms of cardioprotection and 21 years of global research trends in precision prevention (2005-2026).Frontiers in nutrition · 2026Pooled it
- Prevalence of bias attributable to composite outcome in clinical trials published in 2019-2020: a systematic review.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2025Pooled it
- Peripartum cardiomyopathy in an intensive care unit setting.World journal of critical care medicine · 2026Review
- Cardiovascular complications of pregnancy.The Journal of clinical investigation · 2026Review
- Modulation of adipose inflammation and mitochondrial pathways by a yeast-derivedFrontiers in nutrition · 2025Article
- Pharmacological interventions for peripartum cardiomyopathy.The Cochrane database of systematic reviews · 2024Article
- Selenium reduction of ubiquinone via SQOR suppresses ferroptosis.Nature metabolism · 2024Article
- Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy.Current cardiology reviews · 2023Article
- Review
- Article
- Pathophysiology and risk factors of peripartum cardiomyopathy.Nature reviews. Cardiology · 2022Review
- Selenium, TGF-Beta and Infectious Endemic Cardiopathy: Lessons from Benchwork to Clinical Application in Chagas Disease.Biomolecules · 2022Review
- The Impact of Selenium Deficiency on Cardiovascular Function.International journal of molecular sciences · 2021Review
- Key points for the development of antioxidant cocktails to prevent cellular stress and damage caused by reactive oxygen species (ROS) during manned space missions.NPJ microgravity · 2021Review
- Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria.ESC heart failure · 2021Article
- Selenomethionine: A Pink Trojan Redox Horse with Implications in Aging and Various Age-Related Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- Correction to: Selenium supplementation in patients with peripartum cardiomyopathy: a proof‑of‑concept trial.BMC cardiovascular disorders · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe studied the efficacy and safety of selenium supplementation in patients who had peripartum cardiomyopathy (PPCM) and selenium deficiency.
methodsWe randomly assigned 100 PPCM patients with left ventricular ejection fraction (LVEF) < 45% and selenium deficiency (< 70 μg/L) to receive either oral Selenium (L-selenomethionine) 200 μg/day for 3 months or nothing, in addition to recommended therapy, in an open-label randomised trial. The primary outcome was a composite of persistence of heart failure (HF) symptoms, unrecovered LV systolic function (LVEF < 55%) or death from any cause.
resultsOver a median of 19 months, the primary outcome occurred in 36 of 46 patients (78.3%) in the selenium group and in 43 of 54 patients (79.6%) in the control group (hazard ratio [HR] 0.69; 95% confidence interval [CI] 0.43-1.09; p = 0.113). Persistence of HF symptoms occurred in 18 patients (39.1%) in the selenium group and in 37 patients (68.5%) in the control group (HR 0.53; 95% CI 0.30-0.93; p = 0.006). LVEF < 55% occurred in 33 patients (71.7%) in the selenium group and in 38 patients (70.4%) in the control group (HR 0.91; 95% CI 0.57-1.45; p = 0.944). Death from any cause occurred in 3 patients (6.5%) in the selenium group and in 9 patients (16.7%) in the control group (HR 0.37; 95% CI 0.10-1.37; p = 0.137).
conclusionsIn this study, selenium supplementation did not reduce the risk of the primary outcome, but it significantly reduced HF symptoms, and there was a trend towards a reduction of all-cause mortality. CLINICAL
trial registrationClinicalTrials.gov Identifier: NCT03081949.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.